Perspective Therapeutics, Inc. SEC filings CATX
Perspective Therapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Aug 16, 2006. Its latest annual report, Form 10-K, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 16, 2026 | — |
| DEF 14A | Proxy statement | Apr 16, 2026 | Apr 15, 2026 |
| DEFA14A | Additional proxy material | Apr 16, 2025 | — |
| DEF 14A | Proxy statement | Apr 16, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 18, 2024 | — |
| DEF 14A | Proxy statement | Apr 18, 2024 | Apr 18, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2024 | May 31, 2024 |
| DEFA14A | Additional proxy material | Aug 22, 2023 | — |
| DEF 14A | Proxy statement | Aug 22, 2023 | Oct 6, 2023 |
| DEFA14A | Additional proxy material | Jan 12, 2023 | — |
| DEFA14A | Additional proxy material | Dec 14, 2022 | — |
| DEFA14A | Additional proxy material | Dec 6, 2022 | — |
| DEFM14A | Form defm14a | Nov 7, 2022 | — |
| PREM14A | Filing | Oct 25, 2022 | Dec 13, 2022 |
| DEFA14A | Additional proxy material | Oct 24, 2022 | — |
| DEFA14A | Additional proxy material | Sep 28, 2022 | — |
| DEFA14A | Additional proxy material | Oct 25, 2021 | — |
| DEF 14A | Proxy statement | Oct 25, 2021 | Dec 7, 2021 |
| DEFA14A | Additional proxy material | Oct 27, 2020 | — |
| DEF 14A | Proxy statement | Oct 27, 2020 | Dec 8, 2020 |
| DEFA14A | Additional proxy material | Oct 25, 2019 | — |
| DEF 14A | Proxy statement | Oct 25, 2019 | Dec 10, 2019 |
| DEFA14A | Additional proxy material | Nov 9, 2018 | — |
| DEF 14A | Proxy statement | Nov 9, 2018 | Dec 18, 2018 |
| PRE 14A | Preliminary proxy statement | Oct 30, 2018 | Dec 18, 2018 |
| DEFA14A | Additional proxy material | Nov 3, 2017 | — |
| DEF 14A | Proxy statement | Nov 3, 2017 | Dec 14, 2017 |
| DEF 14A | Proxy statement | May 17, 2017 | Jun 15, 2017 |
| PRE 14A | Preliminary proxy statement | May 5, 2017 | May 5, 2017 |
| DEFA14A | Additional proxy material | Nov 4, 2016 | — |
| DEF 14A | Proxy statement | Nov 4, 2016 | Dec 14, 2016 |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 8, 2016 |
| DEFA14A | Additional proxy material | Jan 14, 2015 | — |
| DEF 14A | Proxy statement | Jan 14, 2015 | Feb 27, 2015 |
| DEFA14A | Additional proxy material | Jan 22, 2014 | — |
| DEF 14A | Proxy statement | Jan 21, 2014 | Mar 5, 2014 |
| PRE 14A | Preliminary proxy statement | Dec 24, 2013 | Dec 24, 2013 |
| DEF 14A | Proxy statement | Jan 8, 2013 | Feb 22, 2013 |
| DEF 14A | Proxy statement | Jan 10, 2012 | Feb 24, 2012 |
| DEF 14A | Proxy statement | Jan 11, 2011 | Feb 24, 2011 |
| DEF 14A | Proxy statement | Oct 26, 2009 | Dec 11, 2009 |
| PRE 14A | Preliminary proxy statement | Oct 16, 2009 | Oct 16, 2009 |
| DEF 14A | Proxy statement | Jan 14, 2009 | Feb 18, 2009 |
| DEF 14A | Proxy statement | Jan 14, 2008 | Feb 20, 2008 |
| DEF 14A | Proxy statement | Jan 16, 2007 | Feb 20, 2007 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CATX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 728387
- Former names
- IsoRay, Inc. (until Feb 16, 2023); Isoray, Inc. (until Feb 16, 2023); CENTURY PARK PICTURES CORP (until Aug 3, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.